12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Moxeza moxifloxacin regulatory update

Alcon disclosed in its 4Q10 earnings that FDA approved an NDA for Moxeza ophthalmic solution to treat bacterial conjunctivitis. Moxeza is...

Read the full 81 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >